Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earlier Start Likely For Europe’s Unified Patent Court

Opt-Outs From The System Will Be Possible

Executive Summary

Having cleared numerous hurdles along the way, the proposed new patent system in Europe now appears to be approaching the home straight, with completion forecast for mid-2022. But will a unitary patent with pan-European effect necessarily be the best option in all cases?

You may also be interested in...



German Ruling Opens The Way To European Patent Court

The long-running process of setting up a new European patent court and unitary patent system should shortly be moving into its final phase following a ruling by a German constitutional court.

German Court Ruling Opens The Way To New European Patent Court

The long-running process of setting up a new patent court and unitary patent system should shortly be moving into its final phase.

EU Bodies Agree Clearer Rules On Joint Procurement Of Vaccines & Treatments

The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.

Topics

Latest News
UsernamePublicRestriction

Register

GB151212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel